Mylan NV (MYL) Expected to Post Quarterly Sales of $2.84 Billion

Wall Street analysts expect that Mylan NV (NASDAQ:MYL) will announce $2.84 billion in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Mylan’s earnings, with the lowest sales estimate coming in at $2.75 billion and the highest estimate coming in at $2.90 billion. Mylan posted sales of $2.81 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 1.1%. The firm is expected to report its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Mylan will report full year sales of $11.69 billion for the current fiscal year, with estimates ranging from $11.50 billion to $11.87 billion. For the next fiscal year, analysts expect that the company will post sales of $12.17 billion, with estimates ranging from $11.78 billion to $12.79 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Mylan.

Mylan (NASDAQ:MYL) last issued its earnings results on Tuesday, May 7th. The company reported $0.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.03. The firm had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.96 earnings per share.

Several brokerages have commented on MYL. BidaskClub downgraded Mylan from a “hold” rating to a “sell” rating in a research note on Monday. Raymond James set a $31.00 price target on Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Royal Bank of Canada reduced their price target on Mylan to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. BMO Capital Markets set a $36.00 price target on Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Finally, Morgan Stanley set a $32.00 price target on Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $37.35.

In related news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $27.50, for a total value of $317,157.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.81% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Global Retirement Partners LLC lifted its stake in Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after buying an additional 500 shares during the period. Pinnacle Bank lifted its stake in Mylan by 66.4% in the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after buying an additional 423 shares during the period. Cresset Asset Management LLC acquired a new position in Mylan in the first quarter valued at approximately $41,000. Mascoma Wealth Management LLC acquired a new position in Mylan in the first quarter valued at approximately $47,000. Finally, Kinneret Advisory LLC acquired a new position in Mylan in the fourth quarter valued at approximately $71,000. Institutional investors and hedge funds own 82.73% of the company’s stock.

NASDAQ MYL traded down $0.48 during trading on Friday, hitting $19.17. 6,231,318 shares of the company’s stock were exchanged, compared to its average volume of 6,253,940. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20. The company has a market cap of $10.14 billion, a price-to-earnings ratio of 4.19, a PEG ratio of 1.02 and a beta of 1.44. Mylan has a fifty-two week low of $18.93 and a fifty-two week high of $42.50.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: What is systematic risk?

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit